BRUSSELS — Kimberly-Clark is preparing concessions to address EU antitrust ​concerns about its bid for Tylenol maker Kenvue ‌that could help it win approval for the $40 billion deal after a preliminary review. Kimberly-Clark shares rose more ​than 2.7% on the news in early trading ​while Kenvue gained 2.3%. The maker of Kleenex tissues and ⁠Huggies diapers announced the deal in November last year that ​would add Kenvue’s vast portfolio of brands. …The European Commission is set to ​formally inform Kimberly-Clark of its concerns this week, the ​people said. This would determine whether the company submits concessions by September 29, or waits until it opens a full-scale four-month-long investigation after its preliminary assessment. …The deal was cleared in Australia last week on ​condition Kimberly-Clark divests Kenvue’s Carefree and Stayfree period ​care brands . It secured conditional approval in South Africa last month.